Overview

PCA062 in pCAD-positive Tumors.

Status:
Completed
Trial end date:
2018-07-17
Target enrollment:
Participant gender:
Summary
A first-in-human sttudy using PCA062 in patients with p-CAD positive solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals